Literature DB >> 7866820

One-week low-dose triple therapy for the eradication of Helicobacter pylori infection.

J Labenz1, M Stolte, G H Rühl, T Becker, B Tillenburg, M Sollböhmer, G Börsch.   

Abstract

OBJECTIVE: To evaluate the efficacy and safety of two 1-week low-dose triple therapy regimens for the treatment of Helicobacter pylori infection. PATIENTS AND METHODS: Eighty patients with H. pylori infection and peptic ulcer disease (n = 64) or functional dyspepsia (n = 16), with similar demographic and clinical characteristics, were treated for 1 week with either omeprazole 20 mg once in the morning and clarithromycin 250 mg and metronidazole 400 mg twice daily (OCM; n = 40) or with omeprazole 20 mg once in the morning and clarithromycin 250 mg and tetracycline 500 mg twice daily (OCT; n = 40). H. pylori infection was assessed by urease test, culture and histology performed before and 4 (or more) weeks after cessation of the eradication therapy.
RESULTS: H. pylori infection was treated successfully in 38 out of 40 patients by OCM and in 26 out of 40 patients by OCT (95 versus 65%, respectively; P = 0.0015). The OCM regimen was well tolerated in all patients except for one who complained of epigastric pain. Three patients on the OCT regimen reported side effects (abdominal pain, diarrhoea, pruritus), two of whom discontinued the study medication after 1 day.
CONCLUSIONS: The 1-week low-dose triple therapy comprising omeprazole, clarithromycin and metronidazole was highly effective in eradicating H. pylori and was well tolerated. The replacement of metronidazole by tetracycline resulted in a significant decrease in the eradication rate.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7866820

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  12 in total

Review 1.  Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group.

Authors: 
Journal:  Gut       Date:  1997-07       Impact factor: 23.059

Review 2.  Helicobacter pylori eradication in patients with non-ulcer dyspepsia.

Authors:  H H Xia; N J Talley
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

3.  Helicobacter pylori specific nested PCR assay for the detection of 23S rRNA mutation associated with clarithromycin resistance.

Authors:  S Maeda; H Yoshida; K Ogura; F Kanai; Y Shiratori; M Omata
Journal:  Gut       Date:  1998-09       Impact factor: 23.059

4.  Treating Helicobacter pylori--the best is yet to come?

Authors:  A Harris; J J Misiewicz
Journal:  Gut       Date:  1996-12       Impact factor: 23.059

5.  Detection of clarithromycin-resistant helicobacter pylori strains by a preferential homoduplex formation assay.

Authors:  S Maeda; H Yoshida; H Matsunaga; K Ogura; O Kawamata; Y Shiratori; M Omata
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

Review 6.  Clarithromycin and omeprazole as helicobacter pylori eradication therapy in patients with H. pylori-associated gastric disorders.

Authors:  A Markham; D McTavish
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

7.  Patient factors that predict failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori.

Authors:  P Moayyedi; D M Chalmers; A T Axon
Journal:  J Gastroenterol       Date:  1997-02       Impact factor: 7.527

Review 8.  A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection.

Authors:  A Hackelsberger; P Malfertheiner
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

Review 9.  Diagnostic methods for Helicobacter pylori detection and eradication.

Authors:  A F Goddard; R P H Logan
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

Review 10.  Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs.

Authors:  H D Langtry; M I Wilde
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.